title: Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
authors.affiliation: Research Center of Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
authors.forename: Ciprian
authors.initials: C
authors.lastname: Tomuleasa
authors.forename: Andrei
authors.initials: A
authors.lastname: Cucuianu
authors.forename: Mihaela
authors.initials: M
authors.lastname: Aldea
authors.forename: Ioana
authors.initials: I
authors.lastname: Berindan-Neagoe
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001650:Bile Duct Neoplasms; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma; D054855:Drug-Eluting Stents; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide